99% Purity Semaglutide Powder Raw Powder Semaglutide Peptide Semaglutide

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Semaglutide
• Product Name: Semaglutide
• Name: Semaglutide Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anti-Diabetic
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 910463-68-2
• Mf: C187h291n45o59
• MW: 4113.57754
• Einecs No.: 203-405-2
• Storage Condition: Dry and Ventilated,Store at-20 C
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500 Kg/Month

Product Description

99% Purity Semaglutide Powder Raw Powder Semaglutide Peptide Semaglutide

 

Product Description

Product Details

Product Name	Semaglutide
Appearance	White powder
CAS No.	910463-68-2
MF	C187H291N45O59
MW	4113.57754

Semaglutide is the newest GLP-1R agonist and was approved by the FDA as a once-weekly injection for the treatment of T2DM in late 2017.   The peptide is chemically similar to liraglutide, with the inclusion of two structural modifications (Lau, Bloch, et al., 2015).   The first is the replacement of Gly with the non-proteinogenic amino acid 2-aminoisobutyric acid (Aib) at position 2.   The second is the attachment of octadecanoic diacid to the side chain of Lys-26 through a short polyethylene glycol (PEG) spacer and a γ-glutamic acid linker.   The amino acid substitution renders the peptide more resistant to DPP-4 compared to liraglutide, and the presence of the 18-carbon fatty acid moiety results in a high binding affinity for serum albumin, which translates to a half-life of approximately 7 days in humans.

Application & Function

Semaglutide is a long-acting agonist for human glucagon-like peptide-1 (GLP-1) receptor and is clinically available for the treatment of type 2 diabetes. Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The higher-dose formulation of semaglutide is indicated as an adjunct to diet and exercise for long-term weight management in adults with obesity (initial body mass index (BMI) ≥ 30 kg/m2) or who are overweight (initial BMI ≥ 27 kg/m2) and have at least one weight-related comorbidity.
A review of anti-obesity treatments found that semaglutide as well as tirzepatide (which has an overlapping mechanism of action) were more promising than previous anti-obesity drugs, although less effective than bariatric surgery.

Specification